文献速递类风湿关节炎其他结缔组织病

类风湿关节炎相关间质性肺病的共病与死亡风险:一项基于人群的队列研究

A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality.
PubMed 文献 · Ann Rheum Dis · 2017-06-13

结果显示RA-ILD患者1年、5年和10年死亡率分别为13.9%、39.0%和60.1%,均显著高于无ILD的RA患者,死亡风险比为2至10倍,且在RA-ILD诊断后的最初数月内最高。

要点

  • RA-ILD患者1年死亡率为13.9%,显著高于无ILD RA患者的3.8%。
  • RA-ILD患者10年死亡率达60.1%,无ILD RA患者为34.5%。
  • RA-ILD诊断后最初数月死亡风险比最高,尤其先诊断RA后诊断ILD者。

核心结论

  • ILD是RA的严重并发症,与匹配的无ILD RA患者相比死亡率显著增加。

研究设计与样本

  • 研究为匹配队列研究,在丹麦利用全国前瞻性收集的数据进行。
  • 采用Kaplan-Meier死亡曲线评估死亡风险,并用Cox比例风险回归模型估计死亡风险比(HRR)。

主要发现

  • 34.0%的RA-ILD病例在RA诊断前1年内至诊断后1年内被诊断。
  • RA-ILD患者1年死亡率为13.9%(95% CI 11.4%至16.7%),无ILD RA患者为3.8%(95% CI 3.5%至4.2%)。
  • RA-ILD患者5年死亡率为39.0%(95% CI 34.4%至43.5%),无ILD RA患者为18.2%(95% CI 17.3%至19.1%)。
  • RA-ILD患者10年死亡率为60.1%(95% CI 52.9%至66.5%),无ILD RA患者为34.5%(95% CI 32.8%至36.1%)。

关键数值与推荐

  • 与无ILD的RA相比,RA-ILD的死亡HRR在不同随访期均增加2至10倍。
  • 分层分析显示RA-ILD诊断后最初数月HRR最高,尤其在先诊断RA后诊断ILD的患者中。
  • 男性和Charlson共病指数评估无共病的患者HRR更高。

临床怎么用

  • 对RA患者应警惕ILD的发生,尤其在RA诊断前后1年内。
  • RA-ILD患者死亡风险显著升高,需加强早期识别和综合管理。
  • 男性及无共病的RA-ILD患者死亡风险比更高,临床应关注此类人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare mortality risks in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and patients with RA without ILD. DESIGN: Matched cohort study. SETTING: The study was conducted in Denmark, using nationwide, prospectively collected data. PARTICIPANTS: Among patients with RA diagnosed between 2004 and 2016, 679 patients with RA-ILD were matched for birth year, gender and age at RA diagnosis with 11 722 patients with RA but without ILD. MAIN OUTCOME MEASURES: Mortality risks were assessed using Kaplan-Meier mortality curves, and hazard rate ratios (HRRs) for death were estimated using Cox proportional hazards regression models. RESULTS: The number of prevalent RA patients more than doubled from 15 352 to 35 362 individuals during the study period. RA-ILD was seen in 2.2% of incident RA patients. 34.0% of RA-ILD cases were diagnosed within 1 year prior to and 1 year after the RA diagnosis. One-year mortality was 13.9% (95% CI, 11.4% to 16.7%) in RA-ILD and 3.8% (95% CI, 3.5% to 4.2%) in non-ILD RA, 5-year mortality was 39.0% (34.4% to 43.5%) and 18.2% (17.3% to 19.1%) and 10-year mortality was 60.1% (52.9% to 66.5%) and 34.5% (32.8% to 36.1%), respectively. The HRRs for death were 2 to 10 times increased for RA-ILD compared with non-ILD RA, irrespective of follow-up period. Stratified analysis showed that the HRR for death was highest in the first months after the diagnosis of RA-ILD was made, especially in patients diagnosed with RA before diagnosis of ILD. HRR was higher in males and in patients without comorbidity as assessed by the Charlson Comorbidity Index. CONCLUSIONS: ILD is a serious complication in RA, with a significantly increased mortality compared with a large matched cohort of RA comparisons without ILD.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017. PMID: 28611082. doi:10.1136/annrheumdis-2017-211138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。